U.S. markets closed

Alterity Therapeutics Limited (ATHE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
1.4000-0.0200 (-1.41%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close1.4200
Open1.4100
Bid1.3800 x 4000
Ask1.4500 x 800
Day's Range1.3800 - 1.4499
52 Week Range0.5500 - 5.1500
Volume149,720
Avg. Volume1,516,022
Market Cap46.825M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.6600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Alterity Therapeutics (ASX:ATH) Is In A Good Position To Deliver On Growth Plans
    Simply Wall St.

    Alterity Therapeutics (ASX:ATH) Is In A Good Position To Deliver On Growth Plans

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report
    PR Newswire

    Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report

    Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2021 (Q3 FY21).

  • Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder
    Benzinga

    Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder

    Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. Data were presented at the American Academy of Neurology virtual annual meeting. The data from an animal model of Multiple System Atrophy (MSA) independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor function. MSA is a rare neurodegenerative disorder characterized by autonomic dysfunction, tremors, slow movement, muscle rigidity, and postural instability. The new data indicate that ATH434 preserves neurons not only in the substantia nigra, a main area of pathology in Parkinson's disease but also in the striatum, a region of the brain that integrates information from the cortex and substantia nigra to achieve fine motor control. The study also showed that ATH434 led to reductions in glial cell inclusions, comprised of aggregated α-synuclein, and levels of the toxic form of α-synuclein, both of which are pathological features of MSA. Price Action: ATHE shares are up 22.4% at $1.53 in premarket trading on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaBrii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B StudyTrevena's TRV027 Included In Global COVID-19 Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.